No Pharmacologic Treatment Needed for FRAX 1.9%
A FRAX 10-year major osteoporotic fracture risk of 1.9% is well below treatment thresholds and does not warrant pharmacologic therapy. This patient requires only lifestyle modifications and reassessment based on age and risk factors.
Risk Stratification
Your patient's FRAX score of 1.9% for major osteoporotic fracture falls far below the established treatment thresholds. According to AACE/ACE guidelines, pharmacologic therapy is indicated when:
- 10-year major osteoporotic fracture risk ≥20%, OR
- 10-year hip fracture risk ≥3% 1
At 1.9%, this patient is approximately 10-fold below the treatment threshold for major osteoporotic fractures. The 2025 USPSTF screening trials (SCOOP, ROSE, SOS) enrolled patients with mean FRAX scores of 19-24.6% for major osteoporotic fractures—dramatically higher than your patient 2.
Management Algorithm
Immediate Actions (No Medications)
Lifestyle interventions only:
- Exercise prescription: Weight-bearing, balance, and resistance training twice weekly 1, 3
- Vitamin D supplementation: 400 IU daily minimum per Health Canada recommendations 3
- Calcium intake: Ensure adequate dietary calcium per Health Canada guidelines 3
- Smoking cessation: If applicable 1
- Alcohol limitation: Maximum 2 units per day 1
- Fall risk assessment: Particularly if elderly, with physical therapy referral if indicated 1
Follow-Up Strategy
Screening intervals depend on patient characteristics:
- Women ≥65 years: Prioritize for periodic reassessment with FRAX and consider BMD testing based on risk factors 2, 3
- Women 50-64 years or men ≥50 years: Target screening based on individual risk factors (prior fractures, glucocorticoid use, parental hip fracture, etc.) 3
- Younger patients: Reassess when they reach age-based screening thresholds
Critical Caveats
Do not initiate pharmacologic therapy at this risk level. The evidence is clear that treatment benefits emerge at much higher fracture probabilities. The USPSTF pooled analysis showed screening benefits in populations with mean FRAX scores of 19-24.6%, not 1.9% 2.
However, reassess if:
- Patient sustains a fragility fracture (hip or spine)—this immediately warrants treatment regardless of FRAX 1
- New risk factors emerge (glucocorticoid therapy, multiple falls)
- Patient reaches age 65+ (women) or develops additional risk factors
BMD testing is not urgently needed at this FRAX level unless specific clinical concerns exist (e.g., glucocorticoid therapy, hyperparathyroidism, or other secondary causes of bone loss). The AACE guidelines support using FRAX to guide who needs BMD testing, and this score doesn't meet that threshold 1.
The key message: reassure this patient they have low fracture risk, emphasize lifestyle measures, and establish appropriate follow-up intervals based on their age and sex.